{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:21Z","timestamp":1793212161083,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Comprehensive disease control is an important yet elusive treatment goal in ulcerative colitis (UC). We evaluated the effect of upadacitinib induction and maintenance treatment on composite clinical endpoints and normalization of important health-related quality of life (HRQoL) outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from the U-ACHIEVE and U-ACCOMPLISH trials were analyzed. Clinical responders to upadacitinib 45\u00a0mg 8-week induction were re-randomized 1:1:1 to upadacitinib 30\u00a0mg, 15\u00a0mg, or placebo for 52 weeks of maintenance. The percentage of patients achieving a composite clinical endpoint (clinical remission, complete symptom resolution, and Inflammatory Bowel Disease Questionnaire [IBDQ] remission) and a composite endpoint for normalization of HRQoL outcomes (Functional Assessment of Chronic Illness Therapy-Fatigue, IBDQ remission, Work Productivity and Activity Impairment Questionnaire-Ulcerative Colitis, 36-item Short Form Survey Physical Component Summary and Mental Component Survey, and EuroQol 5-Dimension 5-Level scores) was evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At induction week 8, more patients treated with upadacitinib 45\u00a0mg achieved the composite clinical endpoint vs placebo (6.4% vs 0.9%, P\u2005\u2264\u2005.001) and normalization of the composite HRQoL endpoint (18.9% vs 5.5%, P\u2005\u2264\u2005.001). At maintenance week 52, the composite clinical endpoint was achieved by 18.3% and 13.1% of patients treated with upadacitinib 30\u00a0mg and 15\u00a0mg, respectively, vs 4.5% with placebo (P\u2005\u2264\u2005.001). Normalization of the composite HRQoL endpoint was achieved by 24.0% and 22.3% of patients treated with upadacitinib 30\u00a0mg and 15\u00a0mg, respectively, vs 8.7% for placebo (P\u2005\u2264\u2005.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Upadacitinib may help patients with moderately to severely active UC achieve complete symptom resolution, endoscopic remission, and normalization of HRQoL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical registration numbers<\/jats:title>\n                  <jats:p>U-ACHIEVE (NCT02819635) and U-ACCOMPLISH (NCT03653026)<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf095","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:21:50Z","timestamp":1749460910000},"source":"Crossref","is-referenced-by-count":6,"title":["Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-6902","authenticated-orcid":false,"given":"Julian","family":"Pan\u00e9s","sequence":"first","affiliation":[{"name":"Hospital Clinic Barcelona, IDIPABS, CIBERehd , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai , New York, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Hirosaki General Medical Center, National Hospital Organization , Hirosaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Shukla","sequence":"additional","affiliation":[{"name":"AbbVie Inc., Chicago , IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Dubcenco","sequence":"additional","affiliation":[{"name":"AbbVie Inc., Chicago , IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valencia","family":"Remple","sequence":"additional","affiliation":[{"name":"AbbVie Inc., Chicago , IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Sharma","sequence":"additional","affiliation":[{"name":"AbbVie Inc., Chicago , IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University of Calgary , Calgary, AB ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2025071505214464500_CIT0001","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.dld.2021.03.002","article-title":"Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review","volume":"53","author":"Armuzzi","year":"2021","journal-title":"Dig Liver Dis."},{"key":"2025071505214464500_CIT0002","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","article-title":"Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2025071505214464500_CIT0003","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1007\/s10620-020-06698-1","article-title":"Patient strategies for managing the vicious cycle of fatigue, pain and urgency in inflammatory bowel disease: impact, planning and support","volume":"66","author":"Dibley","year":"2021","journal-title":"Dig Dis Sci."},{"key":"2025071505214464500_CIT0004","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000496739","article-title":"Unmet medical needs in ulcerative colitis: an expert group consensus","volume":"37","author":"Danese","year":"2019","journal-title":"Dig Dis."},{"key":"2025071505214464500_CIT0005","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"key":"2025071505214464500_CIT0006","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/ibd\/izad016","article-title":"Upadacitinib induction and maintenance therapy improves abdominal pain, bowel urgency, and fatigue in patients with ulcerative colitis: a post hoc analysis of phase 3 data","volume":"29","author":"Danese","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2025071505214464500_CIT0007","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/s0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet."},{"key":"2025071505214464500_CIT0008","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1093\/ecco-jcc\/jjab099","article-title":"Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis","volume":"15","author":"Ghosh","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2025071505214464500_CIT0009","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"LoftusColombel","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071505214464500_CIT0010","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s2468-1253(23)00208-x","article-title":"Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025071505214464500_CIT0011","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2025071505214464500_CIT0012","doi-asserted-by":"publisher","first-page":"S641","DOI":"10.14309\/00000434-201210001-01590","article-title":"Time-in-remission analysis of adalimumab versus placebo for the treatment of ulcerative colitis","volume":"107","author":"Sandborn","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"2025071505214464500_CIT0013","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/ecco-jcc\/jjy024","article-title":"Burden of ulcerative colitis on functioning and well-being: a systematic literature review of the SF-36\u00ae health survey","volume":"12","author":"Yarlas","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2025071505214464500_CIT0014","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11136-017-1690-6","article-title":"Psychometric validation of the SF-36(\u00ae) Health Survey in ulcerative colitis: results from a systematic literature review","volume":"27","author":"Yarlas","year":"2018","journal-title":"Qual Life Res."},{"key":"2025071505214464500_CIT0015","first-page":"AS264","article-title":"Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study","volume":"33","author":"WareKosinski","year":"1995","journal-title":"Med Care."},{"key":"2025071505214464500_CIT0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-94-007-7596-1_3","article-title":"Population norms for the EQ-5D","volume-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","author":"Janssen","year":"2014"},{"key":"2025071505214464500_CIT0017","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s12325-023-02473-6","article-title":"Epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (ulcerative colitis and Crohn\u2019s disease) in Spain: a systematic review","volume":"40","author":"Barreiro-de Acosta","year":"2023","journal-title":"Adv Ther."},{"key":"2025071505214464500_CIT0018","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/ceg.S57982","article-title":"Inflammatory bowel disease and anxiety: links, risks, and challenges faced","volume":"8","author":"Bannaga","year":"2015","journal-title":"Clin Exp Gastroenterol"},{"key":"2025071505214464500_CIT0019","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/ibd\/izab016","article-title":"Ulcerative colitis narrative global survey findings: the impact of living with ulcerative colitis-patients\u2019 and physicians\u2019 view","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025071505214464500_CIT0020","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10620-016-4363-3","article-title":"Perceived emotional and psychological impact of ulcerative colitis on outpatients in Spain: UC-LIFE survey","volume":"62","author":"L\u00f3pez-Sanrom\u00e1n","year":"2017","journal-title":"Dig Dis Sci."},{"key":"2025071505214464500_CIT0021","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/mib.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2025071505214464500_CIT0022","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.crohns.2014.03.005","article-title":"IBD and health-related quality of life -- discovering the true impact","volume":"8","author":"L\u00f6nnfors","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2025071505214464500_CIT0023","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00535-016-1241-x","article-title":"Impact of inflammatory bowel disease on Japanese patients\u2019 quality of life: results of a patient questionnaire survey","volume":"52","author":"Ueno","year":"2017","journal-title":"J Gastroenterol."},{"key":"2025071505214464500_CIT0024","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1136\/gutjnl-2016-312307","article-title":"Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf095\/63456060\/jjaf095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/7\/jjaf095\/63456060\/jjaf095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/7\/jjaf095\/63456060\/jjaf095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:21:47Z","timestamp":1752571307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf095\/8158684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf095","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,9]]},"article-number":"jjaf095"}}